Chelsea Therapeutics International Ltd.
(NASDAQ : CHTP)

( )
CHTP After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -6.73%146.810.0%$1534.10m
OCGNOcugen, Inc. -4.19%9.600.0%$1069.86m
NVAXNovavax, Inc. -14.27%205.9992.9%$909.19m
AMGNAmgen, Inc. -0.60%225.691.3%$548.32m
VRTXVertex Pharmaceuticals, Inc. 0.80%212.061.9%$521.91m
REGNRegeneron Pharmaceuticals, Inc. -1.77%454.862.7%$509.91m
ILMNIllumina, Inc. -1.23%441.013.5%$504.66m
GILDGilead Sciences, Inc. 0.88%63.011.0%$479.35m
ALXNAlexion Pharmaceuticals, Inc. -1.05%150.372.0%$354.39m
BNGOBionano Genomics, Inc. -3.66%9.480.0%$340.06m
BIIBBiogen, Inc. -1.24%269.851.7%$329.36m
CRSPCRISPR Therapeutics AG -0.37%129.770.6%$302.39m
EXASEXACT Sciences Corp. -2.72%136.3918.4%$253.67m
SGENSeagen Inc. 0.76%153.715.8%$214.53m
VXRTVaxart, Inc. -5.43%7.140.0%$189.51m

Company Profile

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), and related conditions and diseases along with its development of prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease and cancer. As of December 31, 2009, it was focused on its drug development resources on two clinical stage development projects: droxidopa for symptomatic NOH and other potential indications, and its portfolio of non-metabolized antifolate compounds for the treatment of rheumatoid arthritis.